We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck has issued licenses to five Indian generic drugmakers to produce its COVID-19 antiviral molnupiravir in a move to expand global access to the drug. Read More
As work continues on remedying a host of concerning issues at Emergent BioSolutions’ Bayview, Md., facility, Health Canada has reported that the 1.5 million AstraZeneca (AZ) doses it received from the site were up to par for safety and quality. Read More
The Biden administration has decided to begin sharing its AstraZeneca (AZ) vaccine supply with the rest of the world while the shots go unused in the U.S., as the government also begins delivering supplies of raw materials needed to make the vaccine in COVID-ridden India. Read More
Vertex Pharmaceuticals has forged a partnership with Obsidian Therapeutics to develop new gene therapies based on the control of protein expression by cells. Read More
Six hospital and pharmacy groups have submitted a letter to HHS Secretary Xavier Becerra objecting to drugmakers eliminating 340B drug discounts to contract pharmacies and calling on the department to take a more aggressive stance against such actions, including civil fines. Read More
The EU has made clear that it will set its sights on obtaining additional doses of Pfizer/BioNTech’s and Moderna’s mRNA-based COVID-19 vaccines, opting to pass on pursuing more doses of AstraZeneca (AZ)’s adenoviral-vector vaccine. Read More
Vertex Pharmaceuticals has paid $900 million to CRISPR Therapeutics, a Swiss-American biotech, to amend their collaborative agreement, entitling Vertex to more than half of the profits from future sales of CTX001, their investigational gene therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Read More
The Russian Direct Investment Fund (RDIF), which funded Sputnik V’s development, said the vaccine has now been authorized in more than 60 countries. Read More